



L11 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2002:964186 HCAPLUS Full-text  
 DN 138:24959  
 TI Preparation of macrocycles useful in the treatment of Alzheimer's disease  
 IN Pulley, Shon R.; Beck, James P.; Tenbrink, Ruth E.; Jacobs, Jon S.  
 PA Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company  
 SO PCT Int. Appl., 173 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2002100399	A1	20021219	2002WO-US18719	20020612
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA---2450167	A1	20021219	2002CA-2450167	20020612
	AU2002315098	A1	20021223	2002AU-0315098	20020612
	EP---1395257	A1	20040310	2002EP-0742038	20020612
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR2002010391	A	20040615	2002BR-0010391	20020612
	JP2005505506	T	20050224	2003JP-0503220	20020612
	US2003236240	A1	20031225	2002US-0170331	20020613
	US---7067507	B2	20060627		
	US2006003978	A1	20060105	2005US-0208382	20050819
PRAI	2001US-297505P	P	20010612		
	2001US-333082P	P	20011119		
	2002WO-US18719	W	20020612		
	2002US-0170331	A3	20020613		
OS	MARPAT 138:24959				
GI					



AB Macrocycles I [U is (un)substituted 1,3-dihydroxypropyl, 1-hydroxy-2-aminoethyl, oxiranyl, or 2-oxo-1,3-dioxolan-4-yl; V is (CH<sub>2</sub>)<sub>0-6</sub>; A, B, Y are (un)substituted

alkylene or alkenylene or rings of defined structure; D is CH<sub>2</sub>, CO, or SO<sub>2</sub>; X is absent, O, or an imino group; Z is absent, O, S, an imino group, CO, O<sub>2</sub>C, CO<sub>2</sub>, NHCO, or CONH] were prepared for treating Alzheimer's and similar diseases characterized by the deposition of A $\beta$  peptide in a mammal. Thus, macrocycle II was prepared by a multistep sequence involving reaction of 1-(allyloxy)-5-fluorobenzene with 2-(2,2-dimethyl[1,3]dioxolan-4-yl)aziridine-1-carboxylic acid tert-Bu ester.

IT 477954-35-1P 477954-37-3P 477954-39-5P  
 477954-41-9P 477954-43-1P 477954-44-2P  
 477954-46-4P 477954-48-6P 477954-52-2P  
 477954-55-5P 477954-56-6P 477954-57-7P  
 477954-58-8P 477954-60-2P 477954-61-3P  
 477954-62-4P 477954-64-6P 477954-66-8P  
 477954-68-0P 477954-69-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of macrocycles useful in treatment of Alzheimer's disease)

RN 477954-35-1 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricoso-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[[3-ethylphenyl)methyl]amino]-1-hydroxyethyl]-8-fluoro-20-methyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-37-3 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricoso-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[[1-(3-ethylphenyl)cyclopropyl]amino]-1-hydroxyethyl]-8-fluoro-20-methyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-39-5 HCAPLUS


CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricoso-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[[1-(3-ethynylphenyl)cyclopropyl]amino]-1-hydroxyethyl]-8-fluoro-20-methyl-, (4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 477954-41-9 HCAPLUS  
 CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricosane-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 8-fluoro-4-[(1R)-1-hydroxy-2-[[3-(trifluoromethyl)phenyl]methyl]amino]ethyl-, (4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 477954-43-1 HCAPLUS  
 CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricosane-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[5-ethyl-3-pyridinyl]methyl]amino]-1-hydroxyethyl]-8-fluoro-20-methyl-, (4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 477954-44-2 HCAPLUS  
 CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricosane-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[3-ethylphenyl]methyl]amino]-1-hydroxyethyl]-8-fluoro-20-methyl-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-46-4 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricosane-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[1-(3-ethylphenyl)cyclopropyl]amino]-1-hydroxyethyl]-8-fluoro-20-methyl-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-48-6 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricosane-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 8-fluoro-4-[(1R)-1-hydroxy-2-[[[3-(trifluoromethyl)phenyl]methyl]amino]ethyl]-20-methyl-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-52-2 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricosane-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 8-fluoro-4-[(1R)-1-hydroxy-2-[[[3-(trifluoromethyl)phenyl]methyl]amino]ethyl]-20-methyl-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-55-5 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricosane-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[[(5-ethyl-3-pyridinyl)methyl]amino]-1-hydroxyethyl]-8-fluoro-20-methyl-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-56-6 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricosane-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[[(3-ethylphenyl)methyl]amino]-1-hydroxyethyl]-8-fluoro-20-(2-oxazolyl)-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-57-7 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricosane-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[[1-(3-ethylphenyl)cyclopropyl]amino]-1-hydroxyethyl]-8-fluoro-20-(2-oxazolyl)-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-58-8 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricoso-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[1-(3-ethynylphenyl)cyclopropyl]amino]-1-hydroxyethyl]-8-fluoro-20-(2-oxazolyl)-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-60-2 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricoso-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 8-fluoro-4-[(1R)-1-hydroxy-2-[[[3-(trifluoromethyl)phenyl]methyl]amino]ethyl]-20-(2-oxazolyl)-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 477954-61-3 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricoso-1(22),6,8,10(23),18,20-


hexaene-2,17-dione, 4-[(1R)-2-[[[(5-ethyl-3-pyridinyl)methyl]amino]-1-hydroxyethyl]-8-fluoro-20-(2-oxazolyl)-16-propyl-, (4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 477954-62-4 HCAPLUS  
 CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricos-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[[(3-ethylphenyl)methyl]amino]-1-hydroxyethyl]-8-fluoro-20-(2-oxazolyl)-, (4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 477954-64-6 HCAPLUS  
 CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricos-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[[1-(3-ethylphenyl)cyclopropyl]amino]-1-hydroxyethyl]-8-fluoro-20-(2-oxazolyl)-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-66-8 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricos-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[1-(3-ethynylphenyl)cyclopropyl]amino]-1-hydroxyethyl]-8-fluoro-20-(2-oxazolyl)-, (4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 477954-68-0 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricos-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 8-fluoro-4-[(1R)-1-hydroxy-2-[[[3-(trifluoromethyl)phenyl]methyl]amino]ethyl]-20-(2-oxazolyl)-, (4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 477954-69-1 HCAPLUS

CN 11-Oxa-3,16-diazatricyclo[16.3.1.16,10]tricos-1(22),6,8,10(23),18,20-hexaene-2,17-dione, 4-[(1R)-2-[[[5-ethyl-3-pyridinyl]methyl]amino]-1-hydroxyethyl]-8-fluoro-20-(2-oxazolyl)-, (4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.





# RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Fairlie, D	1996			WO-----9616950 A	HCAPLUS
Fairlie, D	2000	7	1271	JOURNAL OF MEDICINAL	